Cipla’s omeprazole deal will drive sentiment - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Cipla’s omeprazole deal will drive sentiment

Sep 13, 2000

Cipla has finally announced a deal to supply the anti–ulcer bulk drug omeprazole to Andrx Corporation of USA. This is a positive development for the company and one could see the stock rise from current levels. It would be recalled that ‘Prisolec’ (Astra Zeneca’s $ 4.1 bn anti–ulcer blockbuster) is going of patent in October 2001. Andryx is the only company with a tentative approval to market the anti–ulcer drug in the USA and enjoys a six month period of exclusivity post October 2001. Cipla’s tie–up with the former for the exports of the bulk drug could give the company a good growth in exports over the next few years.

Meanwhile, Astra Zeneca has itself developed ‘Nexium’ which it claims a siginificant improvement over its ‘Prilosec’. Initial reports mention that ‘Nexium’ has advantage over ‘Prilosec’ only in severe conditions. The last word, on whether Astra Zeneca can convince regulatory authorities has still not been said.

If however, Andryx were to succeed in its quest for exclusivity, the tentative market size could be in the range of US $ 410 m (Rs 18 bn) even assuming that the prices fall 90% after the period of exclusivity.

At the Annual General Meeting held in the first week of September, Mr. Amar Lulla, the Executive Director of the company was unwilling to talk about the prospects of omeprazole exports to the USA but he did mention that the company was banking on the generic market in the USA for delivering major growth in the future. The company expects an export turnover of Rs 1.8 bn in the current year, which amounts to almost 20% of the company’s turnover. This is likely to increase to 40% over the next 5 years led partially by the present deal.

Interestingly, the company’s own version of omeprazole is undergoing trials in New Zealand and this could lead the company to compete with Andryx in the future.


Equitymaster requests your view! Post a comment on "Cipla’s omeprazole deal will drive sentiment ". Click here!

  

More Views on News

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

I Recommended this Stock over Page Industries because it's Relevant to Doubling Your Income (Profit Hunter)

Sep 7, 2020

Things are not often what they seem in the market and how you can take advantage of this.

The NASDAQ Whale Could Harm Your Portfolio (Fast Profits Daily)

Sep 7, 2020

The discovery of Softbank pushing up prices on the NASDAQ will cause volatility in the market. Stay alert!

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Sep 18, 2020 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS